My remarks on Dr Campbell are based on performance, you are the...

My remarks on Dr Campbell are based on performance, you are the one talking of credentials. I’m talking about the state of the affairs whereby the market is refusing to extend any ‘credit’ until the issue of GMP is resolved. You’re offering a laundry list of individuals that aren’t ultimately in charge of running the activities of the Company: Dr Campbell is. I am saying that the market is pricing PATRYS at the current levels because doubts on the capacity of Dr Campbell to develop the assets of the Company: this guy had more than a decade to deliver a successful GMP run for DX1, that’s what it is. Can PAT DX1 go to human trials? When? Who’s ultimately responsible and accountable if the current run fails again? I think is Dr Campbell. I’m saying that after more than 10 years the leading criterion should be performance rather than credentials as you seem to suggest.